CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
PepCan +1 morebiological
Likely dose
PepCan 50 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03821272
NCT03821272Phase 2Completed
CompareCT.gov

A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients in Remission to Reduce Recurrence Regardless of HPV Status

University of Arkansas·interventional·Posted Jan 29, 2019·Updated Oct 8, 2025

In Brief

A Phase 2 clinical trial evaluating PepCan and Placebo for Head and Neck Cancer. Completed, enrolled 17 participants across 1 site.

Detailed Summary

This study has been designed to evaluate the safety and efficacy of giving seven injections of PepCan or placebo over approximately a 24-month period in subjects with head and neck cancers who achieved remission. PepCan may prove to be beneficial in treating many stages of HPV-related malignancies starting from infection to cancer. Safety, efficacy in terms of reduced cancer recurrence, immunological responses and profiles, and gut microbiome changes will be assessed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 29, 2019
Enrollment StartNov 13, 2019
Primary CompletionFeb 3, 2025
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 7.4 years ago

Interventions

PepCanbiological

50 μg peptide + 0.3mL Candin® per dose administered intradermally in the extremities

Placebobiological

0.9% Saline solution per dose administered intradermally in the extremities